Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report

The histological transformation from adenocarcinoma (ADC) to squamous cell carcinoma (SCC) is rare but recurrently occurs post TKI treatment in EGFR-mutated non-small cell lung cancer patients with a very limited number of clinical cases published. The outcome of patients after SCC onset is poor as...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Junru, Ma, Yutong, Ou, Qiuxiang, Yan, Junrong, Ye, Bin, Li, Yuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178119/
https://www.ncbi.nlm.nih.gov/pubmed/35692748
http://dx.doi.org/10.3389/fonc.2022.883367
_version_ 1784722986866049024
author Ye, Junru
Ma, Yutong
Ou, Qiuxiang
Yan, Junrong
Ye, Bin
Li, Yuping
author_facet Ye, Junru
Ma, Yutong
Ou, Qiuxiang
Yan, Junrong
Ye, Bin
Li, Yuping
author_sort Ye, Junru
collection PubMed
description The histological transformation from adenocarcinoma (ADC) to squamous cell carcinoma (SCC) is rare but recurrently occurs post TKI treatment in EGFR-mutated non-small cell lung cancer patients with a very limited number of clinical cases published. The outcome of patients after SCC onset is poor as no established treatment guidelines were available. Here we report a case who was initially diagnosed with lung ADC with EGFR L858R driver mutation and demonstrated a partial response (PR) to gefitinib for 27 months before disease progression. The rapidly progressive lung metastatic lesions were determined as an SCC histology with positive PD-L1 expression. Besides EGFR L858R, the metastatic SCC harbored the amplification of CD274 and PDCD1LG2 detected by targeted next-generation sequencing (NGS), which encode PD-L1 and PD-L2, respectively. The disease remained stable on the combination therapy of pembrolizumab plus chemotherapy for eight months until the primary ADC lesion progressed. After the failure of progressed primary ADC lesion with radiotherapy and immunotherapy, systemic ADC metastases were developed in multiple locations including kidney, liver, and chest wall with EGFR L858R mutation but negative PD-L1 expression. The patient then received the combination therapy of bevacizumab plus chemotherapy and the disease remained stable for five months. Since August 2021, afatinib has been administrated which led to a PR and the disease has remained stable up till present. This study demonstrated a primary lung ADC who developed systemic ADC metastases and local SCC transformation with distinct molecular features. The patient has achieved long-term clinical benefit upon multiple lines of chemotherapy and immunotherapy, which provided valuable insight into the treatment of advanced SCC-transformed lung ADC patients.
format Online
Article
Text
id pubmed-9178119
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91781192022-06-10 Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report Ye, Junru Ma, Yutong Ou, Qiuxiang Yan, Junrong Ye, Bin Li, Yuping Front Oncol Oncology The histological transformation from adenocarcinoma (ADC) to squamous cell carcinoma (SCC) is rare but recurrently occurs post TKI treatment in EGFR-mutated non-small cell lung cancer patients with a very limited number of clinical cases published. The outcome of patients after SCC onset is poor as no established treatment guidelines were available. Here we report a case who was initially diagnosed with lung ADC with EGFR L858R driver mutation and demonstrated a partial response (PR) to gefitinib for 27 months before disease progression. The rapidly progressive lung metastatic lesions were determined as an SCC histology with positive PD-L1 expression. Besides EGFR L858R, the metastatic SCC harbored the amplification of CD274 and PDCD1LG2 detected by targeted next-generation sequencing (NGS), which encode PD-L1 and PD-L2, respectively. The disease remained stable on the combination therapy of pembrolizumab plus chemotherapy for eight months until the primary ADC lesion progressed. After the failure of progressed primary ADC lesion with radiotherapy and immunotherapy, systemic ADC metastases were developed in multiple locations including kidney, liver, and chest wall with EGFR L858R mutation but negative PD-L1 expression. The patient then received the combination therapy of bevacizumab plus chemotherapy and the disease remained stable for five months. Since August 2021, afatinib has been administrated which led to a PR and the disease has remained stable up till present. This study demonstrated a primary lung ADC who developed systemic ADC metastases and local SCC transformation with distinct molecular features. The patient has achieved long-term clinical benefit upon multiple lines of chemotherapy and immunotherapy, which provided valuable insight into the treatment of advanced SCC-transformed lung ADC patients. Frontiers Media S.A. 2022-05-26 /pmc/articles/PMC9178119/ /pubmed/35692748 http://dx.doi.org/10.3389/fonc.2022.883367 Text en Copyright © 2022 Ye, Ma, Ou, Yan, Ye and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ye, Junru
Ma, Yutong
Ou, Qiuxiang
Yan, Junrong
Ye, Bin
Li, Yuping
Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report
title Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report
title_full Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report
title_fullStr Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report
title_full_unstemmed Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report
title_short Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report
title_sort long-term clinical benefit in egfr-mutant lung adenocarcinoma with local squamous cell carcinoma transformation after egfr tki resistance: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178119/
https://www.ncbi.nlm.nih.gov/pubmed/35692748
http://dx.doi.org/10.3389/fonc.2022.883367
work_keys_str_mv AT yejunru longtermclinicalbenefitinegfrmutantlungadenocarcinomawithlocalsquamouscellcarcinomatransformationafteregfrtkiresistanceacasereport
AT mayutong longtermclinicalbenefitinegfrmutantlungadenocarcinomawithlocalsquamouscellcarcinomatransformationafteregfrtkiresistanceacasereport
AT ouqiuxiang longtermclinicalbenefitinegfrmutantlungadenocarcinomawithlocalsquamouscellcarcinomatransformationafteregfrtkiresistanceacasereport
AT yanjunrong longtermclinicalbenefitinegfrmutantlungadenocarcinomawithlocalsquamouscellcarcinomatransformationafteregfrtkiresistanceacasereport
AT yebin longtermclinicalbenefitinegfrmutantlungadenocarcinomawithlocalsquamouscellcarcinomatransformationafteregfrtkiresistanceacasereport
AT liyuping longtermclinicalbenefitinegfrmutantlungadenocarcinomawithlocalsquamouscellcarcinomatransformationafteregfrtkiresistanceacasereport